Phase 3 Heart Disease Trial, Recruiting (NCT07136012)

Phase 3 Heart Disease Trial, Recruiting NCT07136012 Sponsor: Amgen Condition: Heart Disease

Printed from Voxsanity (voxsanity.com.au) — NCT07136012 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Heart Disease

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

People aged 50 years or older
People whose Lp(a) (a type of cholesterol-like particle in the blood) was measured at 200 nmol/L or higher during the screening process
People who have multiple risk factors for heart and blood vessel disease, and/or signs that fatty deposits have built up in their arteries

Who may not be able to join:

People who have previously had a heart attack, stroke, mini-stroke (TIA), or a sudden loss of blood flow to a limb
People who have previously had, or are planned to have, a procedure to reopen or bypass a blocked artery
People who have a history of serious bleeding disorders

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 28 July 2026

Phase 3: approximately ~65% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.

Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: MD, Amgen

Phone: 866-572-6436

Australian sites

Canberra Hospital, Garran, Australian Capital Territory

Royal Prince Alfred Hospital, Camperdown, New South Wales

Novatrials, Charlestown, New South Wales

Concord Repatriation General Hospital, Concord, New South Wales

Aim Research, Merewether, New South Wales

Orange Health Service, Orange, New South Wales

Wollongong Hospital, Wollongong, New South Wales

Advara HeartCare Wesley, Auchenflower, Queensland

Core Research Group Pty Ltd, Milton, Queensland

University of The Sunshine Coast Clinical Trials, Sippy Downs, Sippy Downs, Queensland

Dr Heart Pty Ltd, Woolloongabba, Queensland

Flinders Medical Centre, Bedford Park, South Australia

Advara HeartCare Leabrook, Leabrook, South Australia

Fusion Clinical Research, Norwood, South Australia

Victorian Heart Hospital, Clayton, Victoria

The Alfred Hospital, Melbourne, Victoria

Momentum Clinical Research - Sunshine, Melbourne, Victoria

Clinitrials - Mandurah, Greenfields, Western Australia

Advara HeartCare Joondalup, Joondalup, Western Australia

Hollywood Private Hospital, Nedlands, Western Australia

Linear Clinical Research Limited, Nedlands, Western Australia

Clinitrials - West Perth, Perth, Western Australia

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT07136012

Sponsor: Amgen

Phase: Phase 3

Status: Recruiting

Condition: Heart Disease

Trial contact: 866-572-6436

More information: https://clinicaltrials.gov/study/NCT07136012

Eligibility summary (AI generated)

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

People aged 50 years or older
People whose Lp(a) (a type of cholesterol-like particle in the blood) was measured at 200 nmol/L or higher during the screening process
People who have multiple risk factors for heart and blood vessel disease, and/or signs that fatty deposits have built up in their arteries

Who may not be able to join:

People who have previously had a heart attack, stroke, mini-stroke (TIA), or a sudden loss of blood flow to a limb
People who have previously had, or are planned to have, a procedure to reopen or bypass a blocked artery
People who have a history of serious bleeding disorders

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 28 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Phase 3

Sponsor

Amgen

Registry

ClinicalTrials.gov

Start date

22 August 2025

Est. completion

20 October 2031

Where this trial is recruiting

🇦🇺 Australia 🇨🇦 Canada 🇺🇸 United States

22 site(s) in Australia. Confirm current status and contact details directly with the trial site.

Primary endpoints

Time to CHD Death, Myocardial Infarction, or Urgent Coronary Revascularization, Whichever Occurs First

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov